Test Detail
Maternal Screen Integrated
Back to Test Directory| Test Description |
|
||||
|---|---|---|---|---|---|
| Screen for risks of Down Syndrome, Trisomy 18, and Open Neural Tube Defect (NTD) using samples drawn during the first and second trimesters. | |||||
| Performed | Avg. Turnaround Time | Method | |||
| Coralville, 8 a.m. - 5 p.m., M-F |
3 - 5 business days | Quantitative Chemiluminescent Immunoassay | |||
| Fee | CPT Code(s) | ||||
| $180.00 | 82105, 82677, 84163, 84702, 86336 | ||||
| Specimen Requirements | |||||
| Specimen Type: | 1 mL Serum, drawn in BOTH first and second trimesters | ||||
| Patient Preparation: | Second sample of a 2-part test drawn between 15 weeks 0 days and 20 weeks 6 days gestation. Requires that the first integrated sample was submitted in the 1st trimester. Screening test for Down Syndrome, Trisomy 18, and Open Neural Tube Defect (NTD) determined using a combination of 1st and 2nd trimester markers with or without a 1st trimester Nuchal Translucency (NT) measurement. | ||||
| Collection Instructions: | Dating by ultrasound Crown Rump Length (CRL). Serum sample drawn in the second trimester between 15 weeks 0 days to 20 weeks 6 days. The date range this sample is to be collected is included in the Maternal Screen Integrated Sample 1 report. Incorrect dating will result in inaccurate risk assessment. Program brochures and patient consent forms are available for order. Red Top Tube: centrifuge and transfer serum to a secondary tube |
||||
| Temperature and Stability: | Refrigerated (2-8°C). Specimen must be received within 9 days of collection. | ||||
| Unacceptable Conditions: | Plasma. Samples not collected within the required gestational age range for the test requested. | ||||
| Expected Results: | |||||
| MoM values for AFP (NTD screen), hCG, Estriol, Inhibin, and Papp-A; Risk Values for Down Syndrome and Trisomy 18; Screen Cutoff established for test; Interpretation/Recommended Action: Negative / No further action or Positive / Level II Ultrasound, counseling and consideration for diagnostic testing. Final Report will be titled Maternal Screen Integrated, since the results come from both Samples 1 and 2. | |||||
| Shipping: | |||||
| Wrap specimen container in absorbent material and place inside a biohazard bag. Transport specimen with cold pack. Ship to the Coralville location. | |||||
| Comments | |||||
| Incorrect information, especially incorrect dating, will result in inaccurate risk assessment. The following information is required for test interpretation: patient demographic information and dating for pregnancy (ultrasound information) should match the information submitted with the Maternal Screen Integrated Sample 1 test. Supply current weight. Test cannot be performed on multiples. Detection rates: 85% Down Syndrome, 80% Trisomy 18, 85% Neural Tube Defects. False Positive Rate: 2.6% without Nuchal Translucency (NT) measurement, 1.9% with Nuchal Translucency (NT) measurement. | |||||
| Alternate Names | |||||
| Second Trimester Screen, Integrated Screen Second Trimester Draw, Integrated Screen | |||||
